ziprasidone ziprasidone ziprasidone, sold under the brand name geodon among others, is an atypical antipsychotic used to treat schizophrenia and bipolar disorder. it may be used by mouth and by injection into a muscle (im). the im form may be used for acute agitation in people with schizophrenia. ziprasidoneclinical datatrade namesgeodon, zeldox, zipwell, otherahfs/drugs.commonographmedlineplusa699062license data us dailymed: ziprasidone us fda: ziprasidone pregnancycategory au: c routes ofadministrationby mouth, intramuscular injection (im)drug classatypical antipsychoticatc coden05ae04 (who) legal statuslegal status au: s4 (prescription only) us: ℞-only pharmacokinetic databioavailability60% (oral) 100% (im)metabolismliver (aldehyde reductase)elimination half-life7 to 10 hoursexcretionurine and fecesidentifiers iupac name 5--6-chloro-1,3-dihydro-2h-indol-2-one cas number146939-27-7 ypubchem cid60854iuphar/bps59drugbankdb00246 ychemspider54841 yunii6uka5vej6xkeggd08687 ychebichebi:10119 ychemblchembl708 ycomptox dashboard (epa)dtxsid4023753 echa infocard100.106.954 chemical and physical dataformulac21h21cln4osmolar mass412.94 g·mol−13d model (jsmol)interactive image smiles o=c1cc2c(n1)cc(cl)c(c2)ccn3ccn(cc3)c4nsc5ccccc45 inchi inchi=1s/c21h21cln4os/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13h,5-10,12h2,(h,23,27) ykey:mvwvfyhbgmafly-uhfffaoysa-n y (verify) common side effects include dizziness, drowsiness, dry mouth, and twitches. although it can also cause weight gain, the risk is much lower than for other atypical antipsychotics. how it works is not entirely clear but is believed to involve effects on serotonin and dopamine in the brain. ziprasidone was approved for medical use in the united states in 2001. the pills are made up of the hydrochloride salt, ziprasidone hydrochloride. the intramuscular form is the mesylate, ziprasidone mesylate trihydrate, and is provided as a lyophilized powder. in 2020, it was the 282nd most commonly prescribed medication in the united states, with more than 1 million prescriptions. medical uses ziprasidone is approved by the u.s. food and drug administration (fda) for the treatment of schizophrenia as well as acute mania and mixed states associated with bipolar disorder. its intramuscular injection form is approved for acute agitation in schizophrenic patients for whom treatment with just ziprasidone is appropriate. in a 2013 study in a comparison of 15 antipsychotic drugs in effectiveness in treating schizophrenic symptoms, ziprasidone demonstrated mild-standard effectiveness. 15% more effective than lurasidone and iloperidone, approximately as effective as chlorpromazine and asenapine, and 9–13% less effective than haloperidol, quetiapine, and aripiprazole. ziprasidone is effective in the treatment of schizophrenia, though evidence from the catie trials suggests it is less effective than olanzapine, and equally as effective compared to quetiapine. there are higher discontinuation rates for lower doses of ziprasidone, which are also less effective than higher doses. adverse effects ziprasidone (and all other second generation antipsychotics (sgas)) received a black box warning due to increased mortality in elderly patients with dementia-related psychosis. sleepiness and headache are very common adverse effects (>10%). common adverse effects (1–10%), include producing too much saliva or having dry mouth, runny nose, respiratory disorders or coughing, nausea and vomiting, stomach aches, constipation or diarrhea, loss of appetite, weight gain (but the smallest risk for weight gain compared to other antipsychotics), rashes, fast heart beats, blood pressure falling when standing up quickly, muscle pain, weakness, twitches, dizziness, and anxiety. extrapyramidal symptoms are also common and include tremor, dystonia (sustained or repetitive muscle contractions), akathisia (the feeling of a need to be in motion), parkinsonism, and muscle rigidity; in a 2013 meta-analysis of 15 antipsychotic drugs, ziprasidone ranked 8th for such side effects. ziprasidone is known to trigger mania in some bipolar patients. this medication can cause birth defects, according to animal studies, although this side effect has not been confirmed in humans. recently, the fda required the manufacturers of some atypical antipsychotics to include a warning about the risk of hyperglycemia and type ii diabetes with atypical antipsychotics. some evidence suggests that ziprasidone does not cause insulin resistance to the degree of other atypical antipsychotics, such as olanzapine. weight gain is also less of a concern with ziprasidone compared to other atypical antipsychotics. in fact, in a trial of long term therapy with ziprasidone, overweight patients (bmi > 27) actually had a mean weight loss overall. according to the manufacturer insert, ziprasidone caused an average weight gain of 2.2 kg (4.8 lbs), which is significantly lower than other atypical antipsychotics, making this medication better for patients that are concerned about their weight. in december 2014, the fda warned that ziprasidone could cause a potentially fatal skin reaction, drug reaction with eosinophilia and systemic symptoms, although this was believed to occur only rarely. discontinuation the british national formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse. symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite. other symptoms may include restlessness, increased sweating, and trouble sleeping. less commonly there may be a feeling of the world spinning, numbness, or muscle pains. symptoms generally resolve after a short period of time. there is tentative evidence that discontinuation of antipsychotics can result in psychosis. it may also result in reoccurrence of the condition that is being treated. rarely tardive dyskinesia can occur when the medication is stopped. pharmacology pharmacodynamics